摘要
目的：通过研究乳腺原发性弥漫性大B细胞性淋巴瘤（DLBCL）的临床病理特征及免疫表型，探讨乳腺DLBCL的诊疗及预后。方法：按2008年WHO淋巴瘤分类标准，收集31例乳腺原发性DLBCL，分析其临床病理特征、免疫分型并进行诊疗随访。结果：按Ann Arbor分期标准，Ⅰ期15例，Ⅱ期14例，Ⅲ期1例，Ⅳ期1例。镜下多呈现肿瘤性淋巴细胞弥漫浸润分布，呈“哨兵样”排列，残存乳腺结构。可行免疫分型的病例均为非生发中心B细胞（GCB）型。31例患者中29例患者有完整的随访资料，随访时间5年，其中16例存活，13例死亡，生存时间5~41个月。结论：乳腺原发性DLBLC免疫表型多为非GCB型，免疫组化标记有助于确诊，治疗以手术联合化疗、放疗等为宜。
Objective：To study the clinicopathological features and immunophenotype of breast primary diffuse large B-cell lymphoma（DLBCL）, to explore the diagnosis and prognosis of breast DLBCL. Method：According to 2008 WHO lymphoma classification criteria,collected 31 cases of breast primary DLBCL,analyzed its clinicopathological features and immunophenotyping,as well as carried on the diagnosis and follow-up. Result：According to the Ann Arbor staging criteria,15 cases were in stageⅠ,14 cases were in stageⅡ,1 case was in stageⅢand 1 case was in stageⅣ. Microscope showed that more tumor lymphatic cells are diffuse infiltration distribution,and present an arrangement like the“sentry type”,and remain the breast structure. Feasible immunophenotype cases were all non-germinal center B cells type（GCB）. Among the 31 patients,29 patients had the complete follow-up data,in 5-year’s follow-up period,16 patients survived and 13 died,survival time was from 5 to 41 months. Conclusion：Breast primary DLBLC immunophenotype are more non-GCB types,immunohistochemical markers are helpful in diagnosis,it is appropriate to use surgery combination chemotherapy and radiotherapy.
出处
《中国医学创新》
CAS
2014年第3期54-56,共3页
Medical Innovation of China
